Cetera Investment Advisers lifted its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 321.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 165,220 shares of the exchange traded fund’s stock after purchasing an additional 126,053 shares during the period. Cetera Investment Advisers owned about 0.22% of SPDR S&P Biotech ETF worth $15,678,000 as of its most recent filing with the SEC.
A number of other hedge funds have also bought and sold shares of XBI. Avoro Capital Advisors LLC acquired a new stake in shares of SPDR S&P Biotech ETF in the 4th quarter worth approximately $396,844,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in SPDR S&P Biotech ETF by 30.3% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,136,000 shares of the exchange traded fund’s stock worth $297,575,000 after purchasing an additional 730,000 shares during the period. Jane Street Group LLC boosted its stake in SPDR S&P Biotech ETF by 68.7% during the 1st quarter. Jane Street Group LLC now owns 961,082 shares of the exchange traded fund’s stock valued at $91,197,000 after purchasing an additional 391,333 shares in the last quarter. Baymount Management LP acquired a new position in shares of SPDR S&P Biotech ETF during the 1st quarter valued at $34,160,000. Finally, Blackstone Inc. raised its stake in shares of SPDR S&P Biotech ETF by 674.8% in the 4th quarter. Blackstone Inc. now owns 337,030 shares of the exchange traded fund’s stock worth $30,093,000 after buying an additional 293,530 shares in the last quarter.
SPDR S&P Biotech ETF Trading Down 2.2 %
NYSEARCA:XBI opened at $96.47 on Friday. The company has a 50-day moving average of $94.26 and a 200-day moving average of $92.29. The firm has a market cap of $7.35 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a twelve month low of $63.80 and a twelve month high of $103.52.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Compound Interest and Why It Matters When Investing
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Calculate Return on Investment (ROI)
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.